Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) on May 22, 2023, started off the session at the price of $32.63, soaring 4.74% from the previous trading day. During the day, the shares moved up to $34.26 and dropped to $32.63 before settling in for the closing price of $32.46. Within the past 52 weeks, CERE’s price has moved between $22.10 and $41.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -40.80%. With a float of $128.77 million, this company’s outstanding shares have now reached $156.65 million.
The firm has a total of 319 workers. Let’s measure their productivity.
Cerevel Therapeutics Holdings Inc. (CERE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cerevel Therapeutics Holdings Inc. is 17.56%, while institutional ownership is 86.00%. The most recent insider transaction that took place on May 04, was worth 1,573,434. In this transaction CEO and Chairperson of this company sold 50,000 shares at a rate of $31.47, taking the stock ownership to the 2,704 shares. Before that another transaction happened on Apr 11, when Company’s CEO and Chairperson sold 50,000 for $25.06, making the entire transaction worth $1,253,130. This insider now owns 2,704 shares in total.
Cerevel Therapeutics Holdings Inc. (CERE) Earnings and Forecasts
As on 3/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.67 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.67) by $0. This company achieved a return on equity of -63.91. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -40.80% per share during the next fiscal year.
Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) Trading Performance Indicators
Cerevel Therapeutics Holdings Inc. (CERE) is currently performing well based on its current performance indicators. A quick ratio of 13.40 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.52, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.82 in one year’s time.
Technical Analysis of Cerevel Therapeutics Holdings Inc. (CERE)
Analysing the last 5-days average volume posted by the [Cerevel Therapeutics Holdings Inc., CERE], we can find that recorded value of 0.43 million was lower than the volume posted last year of 0.6 million. As of the previous 9 days, the stock’s Stochastic %D was 68.57%. Additionally, its Average True Range was 1.50.
During the past 100 days, Cerevel Therapeutics Holdings Inc.’s (CERE) raw stochastic average was set at 85.62%, which indicates a significant decrease from 96.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.42% in the past 14 days, which was lower than the 49.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.42, while its 200-day Moving Average is $29.25. Now, the first resistance to watch is $34.63. This is followed by the second major resistance level at $35.26. The third major resistance level sits at $36.26. If the price goes on to break the first support level at $33.00, it is likely to go to the next support level at $32.00. Should the price break the second support level, the third support level stands at $31.37.
Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) Key Stats
Market capitalization of the company is 5.25 billion based on 156,833K outstanding shares. Right now, sales total 0 K and income totals -351,510 K. The company made 0 K in profit during its latest quarter, and -104,290 K in sales during its previous quarter.
